Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume
Non-prescription and compounded peptides such as BPC-157, CJC-1295, and MOTS-c generally carry less robust clinical evidence for weight-loss magnitude and timelines than GLP-1 drugs
Our clinic offers two strengths of Methylcobalamin B12, 1mg/1ml and 5mg/1ml for self-injection
Understanding the full landscape is what allows a clinician to place MIC injections honestly
I feel better and look better than before the shots Hello, this is the best company.their products are of the finest quality
People living with diabetes should note any new or worsening symptoms they experience
